Trial Profile
A Multicentric Study (R.E.P. - Apulian Hematology Network) to Assess Efficacy and Safety of Ibrutinib Therapy in Relapsed/Refractory Mantle Cell Lymphoma in Real-Life context.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2017
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 21 Jul 2017 New trial record
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association